Medtronic Spine Growth Stymied by COVID Headwinds

Medtronic reported fiscal 2Q22 orthopedic sales of $777.6 million, +1% vs. fiscal 2Q21. Like its peers, the company faced end-market headwinds due to COVID's impact on procedure volumes and critical staffing shortages in hospitals. For the fiscal year 2022, Medtronic lowered its previous guidance of 9% growth to a range of 7% to 8%. The...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us